While the role that PRMT5 plays in the development of HCC is largely circumstantial—elevated PRMT5 levels clearly correlate with the promotion of HCC and poor prognosis of these cancer patients—its effector molecule, SND1, is more solidly implicated as a driver of HCC. The gene discussed is PRMT5; the disease is cancer.